NASDAQ: SCTXScribe Therapeutics Inc Stock Ownership - Who owns Scribe Therapeutics?
Insider buying vs selling
Have Scribe Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Behzad Aghazadeh | Director | 2026-07-28 | 7,905 | $18.25 | $144.27kBuy |
| Carl L. Gordon | Director | 2026-07-27 | 1,000,000 | $15.00 | $15.00MBuy |
| Orbimed Advisors LLC | Director | 2026-07-27 | 1,000,000 | $15.00 | $15.00MBuy |
| Ah Bio Fund II LP | 10% Owner | 2026-07-27 | 333,333 | $15.00 | $5.00MBuy |
| Behzad Aghazadeh | Director | 2026-07-24 | 2,333,333 | $15.00 | $35.00MBuy |
| Behzad Aghazadeh | Director | 2026-07-24 | 50,000 | $22.31 | $1.12MBuy |
| Svetlana Lucas | CXO | 2026-07-23 | 3,000 | $15.00 | $45.00kBuy |
| David Parrot | CFO | 2026-07-23 | 1,333 | $15.00 | $20.00kBuy |
| David Parrot | CFO | 2026-07-23 | 1,333 | $15.00 | $20.00kBuy |
SCTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when SCTX insiders and whales buy or sell their stock.
SCTX Shareholders
What type of owners hold Scribe Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Behzad Aghazadeh | 16.32% | 3,088,888 | $91.03M | Insider |
| Ah Bio Fund II LP | 16.28% | 3,082,725 | $90.85M | Insider |
| Orbimed Advisors LLC | 7.12% | 1,348,825 | $39.75M | Insider |
| Carl L. Gordon | 7.12% | 1,348,825 | $39.75M | Insider |
| Lilly Co Eli | 5.57% | 1,054,828 | $31.09M | Insider |
| Jennifer A. Doudna | 3.19% | 603,547 | $17.79M | Insider |
| Brett Staahl | 2.77% | 524,336 | $15.45M | Insider |
| Benjamin L. Oakes | 2.68% | 506,602 | $14.93M | Insider |
| Svetlana Lucas | 0.18% | 33,695 | $992.99k | Insider |
| David Parrot | 0.01% | 2,666 | $78.57k | Insider |
SCTX vs Biotech Stocks
Scribe Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.